Private Advisory Group LLC Sells 1,990 Shares of Eli Lilly and Company $LLY

Private Advisory Group LLC trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 11.1% during the third quarter, Holdings Channel.com reports. The firm owned 15,942 shares of the company’s stock after selling 1,990 shares during the period. Eli Lilly and Company accounts for about 1.0% of Private Advisory Group LLC’s holdings, making the stock its 22nd largest holding. Private Advisory Group LLC’s holdings in Eli Lilly and Company were worth $18,446,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LLY. Torren Management LLC lifted its stake in shares of Eli Lilly and Company by 357.1% during the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after buying an additional 25 shares during the period. Marshall & Sterling Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $49,000. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $42,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $64,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Investors following LLY have been watching these news items:

  • Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania facility to make injectable medicines, including next-generation candidate retatrutide. The investment could expand manufacturing capacity for future demand and is expected to create 850 permanent jobs, though the benefits will take time to materialize. Lilly facility announcement
  • Positive Sentiment: New trial coverage points to broader potential for Lilly’s GLP-1 medicines: orforglipron reportedly showed promise for osteoarthritic knee pain, and Foundayo data indicated improvement in sleep apnea. These possible benefits could expand the drugs’ addressable markets, but further development and evidence remain important. Trial results coverage
  • Neutral Sentiment: Lilly’s obesity collaboration with Fauna Bio designated a second discovery target using AI-based research. It adds to the early-stage pipeline, but any commercial impact is uncertain and likely years away. Fauna Bio announcement

Insider Buying and Selling

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 0.3%

Shares of LLY stock opened at $1,433.34 on Friday. The firm has a market cap of $1.35 trillion, a P/E ratio of 46.52, a PEG ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm’s 50-day simple moving average is $1,236.58 and its 200-day simple moving average is $1,108.27.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period last year, the company earned $7.02 earnings per share. The company’s quarterly revenue was up 38.6% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. UBS Group boosted their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. TD Cowen reissued a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. China Merchants Securities cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday. Truist Financial reaffirmed a “buy” rating and issued a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,416.64.

Get Our Latest Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.